中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2014年
21期
154-156
,共3页
2型糖尿病%地特胰岛素%门冬胰岛素30%起始治疗
2型糖尿病%地特胰島素%門鼕胰島素30%起始治療
2형당뇨병%지특이도소%문동이도소30%기시치료
Type 2 diabetes%Insulin detemir%Insulin aspart 30%Starting treatment
目的：对HbA1c>9%的新诊断的T2DM患者进行地特胰岛素（Det）联合二甲双胍的短期强化治疗，探讨Det作为基础胰岛素在T2DM起始治疗中的疗效与安全性。方法：156例新诊断的T2DM患者随机数字表法分为治疗组与对照组，每组78例，两组在口服二甲双胍的基础上，治疗组给予Det联合二甲双胍治疗，对照组给予门冬胰岛素30联合二甲双胍治疗，治疗12周。对其治疗前后血糖控制、低血糖情况和HOMA-β功能进行自身及组间比较。结果：12周治疗后，两组中FBG、2 h PBG、HBA1c较治疗前均明显下降，FC-P、2 h C-P和HOMA-β较治疗前明显升高（P<0.01）。治疗组低血糖发生率3.85%（3/78）、症状性低血糖1例，对照组24.36%（19/78）、症状性低血糖5例，Det明显优于门冬胰岛素30，比较差异有统计学意义（P<0.01）。结论：Det作为基础胰岛素联合二甲双胍治疗新诊断时HbA1c>9%的T2DM患者可以良好控制高血糖且低血糖发生率低，是一种简单、有效、安全的门诊强化治疗方案，适合初诊2型糖尿病的起始治疗。
目的：對HbA1c>9%的新診斷的T2DM患者進行地特胰島素（Det）聯閤二甲雙胍的短期彊化治療，探討Det作為基礎胰島素在T2DM起始治療中的療效與安全性。方法：156例新診斷的T2DM患者隨機數字錶法分為治療組與對照組，每組78例，兩組在口服二甲雙胍的基礎上，治療組給予Det聯閤二甲雙胍治療，對照組給予門鼕胰島素30聯閤二甲雙胍治療，治療12週。對其治療前後血糖控製、低血糖情況和HOMA-β功能進行自身及組間比較。結果：12週治療後，兩組中FBG、2 h PBG、HBA1c較治療前均明顯下降，FC-P、2 h C-P和HOMA-β較治療前明顯升高（P<0.01）。治療組低血糖髮生率3.85%（3/78）、癥狀性低血糖1例，對照組24.36%（19/78）、癥狀性低血糖5例，Det明顯優于門鼕胰島素30，比較差異有統計學意義（P<0.01）。結論：Det作為基礎胰島素聯閤二甲雙胍治療新診斷時HbA1c>9%的T2DM患者可以良好控製高血糖且低血糖髮生率低，是一種簡單、有效、安全的門診彊化治療方案，適閤初診2型糖尿病的起始治療。
목적：대HbA1c>9%적신진단적T2DM환자진행지특이도소（Det）연합이갑쌍고적단기강화치료，탐토Det작위기출이도소재T2DM기시치료중적료효여안전성。방법：156례신진단적T2DM환자수궤수자표법분위치료조여대조조，매조78례，량조재구복이갑쌍고적기출상，치료조급여Det연합이갑쌍고치료，대조조급여문동이도소30연합이갑쌍고치료，치료12주。대기치료전후혈당공제、저혈당정황화HOMA-β공능진행자신급조간비교。결과：12주치료후，량조중FBG、2 h PBG、HBA1c교치료전균명현하강，FC-P、2 h C-P화HOMA-β교치료전명현승고（P<0.01）。치료조저혈당발생솔3.85%（3/78）、증상성저혈당1례，대조조24.36%（19/78）、증상성저혈당5례，Det명현우우문동이도소30，비교차이유통계학의의（P<0.01）。결론：Det작위기출이도소연합이갑쌍고치료신진단시HbA1c>9%적T2DM환자가이량호공제고혈당차저혈당발생솔저，시일충간단、유효、안전적문진강화치료방안，괄합초진2형당뇨병적기시치료。
T2DM patients with HbA1c>9%were newly diagnosed insulin detemir(Det)combined short-term intensive treatment with metformin explore Det as the basis for the initial treatment of insulin in T2DM efficacy and safety. Method:156 newly diagnosed T2DM patients were randomly divided into treatment group and control group, and 78 cases in each group. The two groups on the basis of oral metformin,the treatment group was given metformin therapy Det,the control group was given insulin aspart 30 combined metformin for 12 weeks. Their blood glucose control before and after treatment,low blood glucose and HOMA-βfunction between themselves were compared. Result:After 12 weeks of treatment,both groups FBG,2 h PBG,HBA1c were significantly lower than before treatment,FC-P,before 2 h C-P and HOMA-βwere significantly higher than before treatment(P<0.01). Incidence of hypoglycemia in the treatment group was 3.85%(3/78),one case of symptomatic hypoglycemia,24.36%in the control group(19/78),five cases of symptomatic hypoglycemia,Det was much better than insulin aspart 30(P<0.01),the difference was statistically significant. Conclusion:When Det as basal insulin combined with metformin therapy in newly diagnosed HbA1c>9%of patients with T2DM can be well controlled high blood sugar and low incidence of hypoglycemia is a simple,effective and safe outpatient intensive treatment program for newly diagnosed type 2 initial treatment of diabetes.
